Journal article
Precision Oncology in Colorectal Cancers- Therapeutics and Beyond (CME article)
International Journal of Cancer Care and Delivery, Vol.2(1), pp.1-11
03/28/2022
DOI: 10.53876/001c.33571
Abstract
Incidence and mortality of colorectal cancers (CRC) have decreased among patients older than 65 years but increased among younger than 65, especially under 50 years of age. Precision medicine has improved outcomes through targeted therapies based on molecular features, gene expression, and other features of tumors. Newer risk prediction models like genetic risk score (G-score) were shown to increase discriminatory accuracy that further refines CRC risk. Non-invasive blood-based tests like the mSEPT9 assay have the potential to improve CRC screening rates. CRCs are classified into four consensus molecular subtypes (CMS) based on gene expression analyses and into intrinsic subtypes (CRIS) based on specific molecular, functional, and pathogenic features. Liquid biopsy has the potential to be at the forefront of CRC screening, diagnosis, post-treatment mutational analysis, and treatment decisions. Next-generation sequencing has an evolving role in early-stage disease to reduce recurrence risk and enable tailored adjuvant therapy. Targeted therapy like EGFR inhibitors, VEGF inhibitors, and anti-HER-2 agents have improved outcomes in metastatic CRCs. Patient-Derived Organoids can recapitulate tumor-specific characteristics and may play a valuable role in precision oncology. Artificial intelligence and machine learning will expedite comprehensive genomic profiling and create signatures of individual cancers that can help develop targeted therapy.
Details
- Title: Subtitle
- Precision Oncology in Colorectal Cancers- Therapeutics and Beyond (CME article)
- Creators
- Janeesh Sekkath VeeduJill Kolesar - University of KentuckyChaitanya Iragavarapu - University of Kentucky
- Resource Type
- Journal article
- Publication Details
- International Journal of Cancer Care and Delivery, Vol.2(1), pp.1-11
- DOI
- 10.53876/001c.33571
- ISSN
- 2770-3533
- eISSN
- 2770-3533
- Language
- English
- Date published
- 03/28/2022
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696538302771
Metrics
1 Record Views